| Sep 25 | Sep 24 | Sep 23 | Sep 22 | Sep 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 878.94K | $ 811.29K | $ 792.63K | $ 853.51K | $ 1.00M |
| Gross Profit | $ 718.09K | $ 653.50K | $ 635.99K | $ 680.19K | $ 804.21K |
| Operating Income | $ 87.02K | $ 68.30K | $ -25.34K | $ -116.77K | $ -26.79K |
| EBITDA | $ 129.44K | $ 112.04K | $ 6.68K | $ 16.46K | $ 108.22K |
| Net Income | $ 121.98K | $ 106.70K | $ 1.55K | $ 21.28K | $ 95.99K |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 1.22M | $ 1.27M | $ 1.17M | $ 1.23M | $ 1.31M |
| Total Assets | $ 2.00M | $ 1.95M | $ 1.53M | $ 1.51M | $ 1.63M |
| Total Debt | $ 287.18K | $ 340.04K | $ 43.84K | $ 0.00 | $ 101.02K |
| Net Debt | $ -377.92K | $ -77.27K | $ -313.14K | $ -1.23M | $ -420.53K |
| Total Liabilities | $ 348.18K | $ 381.17K | $ 78.99K | $ 68.24K | $ 201.61K |
| Stockholders' Equity | $ 1.65M | $ 1.57M | $ 1.46M | $ 1.44M | $ 1.43M |
| Cash Flow | |||||
| Free Cash Flow | $ -8.68K | $ 98.60K | $ -59.96K | $ 31.25K | $ 28.89K |
| Operating Cash Flow | $ -7.28K | $ 98.60K | $ -59.11K | $ 40.62K | $ 31.99K |
| Investing Cash Flow | $ 294.08K | $ -38.28K | $ -816.38K | $ 685.30K | $ 12.08K |
| Financing Cash Flow | $ -39.00K | $ 0.00 | $ 0.00 | $ -15.00K | $ 101.02K |
InVitro International (IVRO)
OTHER OTC:IVRO
